Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Frank Stephen Hodi, M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
D510, Adult Oncology
44 Binney St
Boston MA 02115
Phone617/632-5053
Fax617/632-3987

 Mentoring 
 completed student projects
Novel HSP90 and EGFR inhibitors as potential therapeutics for melanoma
Full Time/Year Long, 08/29/11 - 05/04/12

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, Flaherty K, Cranmer L, Hodi FS, Day BM, Linke R, Hainsworth J. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24.
    View in: PubMed
  2. O'Regan K, Breen M, Ramaiya N, Jagannathan J, Dipiro PJ, Hodi FS, Van den Abbeele AD. Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging. 2013; 13(4):626-32.
    View in: PubMed
  3. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clin Cancer Res. 2013 Oct 1; 19(19):5300-9.
    View in: PubMed
  4. Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, Suh JH, Vogelbaum MA, Mehta MP, Dancey J, Linskey ME, Camidge DR, Aoyama H, Brown PD, Chang SM, Kalkanis SN, Barani IJ, Baumert BG, Gaspar LE, Hodi FS, Macdonald DR, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e407-16.
    View in: PubMed
  5. Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge DR, Chang SM, Dancey J, Gaspar LE, Harris GJ, Hodi FS, Kalkanis SN, Lamborn KR, Linskey ME, Macdonald DR, Margolin K, Mehta MP, Schiff D, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Wen PY. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol. 2013 Sep; 14(10):e396-406.
    View in: PubMed
  6. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 Oct; 10(10):588-98.
    View in: PubMed
  7. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95.
    View in: PubMed
  8. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
  9. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013; 18(6):733-43.
    View in: PubMed
  10. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013 Jul; 1291(1):1-13.
    View in: PubMed
  11. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14):3936-43.
    View in: PubMed
  12. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44.
    View in: PubMed
  13. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013; 18(6):726-32.
    View in: PubMed
  14. Luke JJ, Hodi FS. Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. Oncologist. 2013; 18(6):717-25.
    View in: PubMed
  15. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013 Apr 4; 368(14):1365-6.
    View in: PubMed
  16. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Apr 1; 11(4):395-407.
    View in: PubMed
  17. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res. 2013 Apr 15; 19(8):2232-9.
    View in: PubMed
  18. Wu X, Marmarelis ME, Hodi FS. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One. 2013; 8(2):e56134.
    View in: PubMed
  19. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013 May 1; 119(9):1675-82.
    View in: PubMed
  20. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clin Cancer Res. 2013 Mar 1; 19(5):1225-31.
    View in: PubMed
  21. Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. Clin Cancer Res. 2013 Feb 1; 19(3):598-609.
    View in: PubMed
  22. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012 Dec 15; 18(24):6580-7.
    View in: PubMed
  23. Oxnard GR, Morris MJ, Hodi FS, Baker LH, Kris MG, Venook AP, Schwartz LH. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012 Oct 17; 104(20):1534-41.
    View in: PubMed
  24. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012; 10:83.
    View in: PubMed
  25. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28; 366(26):2443-54.
    View in: PubMed
  26. Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-?B pathways. Mol Cancer Ther. 2012 Sep; 11(9):1905-14.
    View in: PubMed
  27. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012 May; 12(5):349-61.
    View in: PubMed
  28. Wu X, Zhou J, Rogers AM, Jänne PA, Benedettini E, Loda M, Hodi FS. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 2012 Apr; 22(2):123-32.
    View in: PubMed
  29. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May; 13(5):459-65.
    View in: PubMed
  30. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc Netw. 2012 Mar; 10(3):366-400.
    View in: PubMed
  31. Alloo A, Garibyan L, LeBoeuf N, Lin G, Werchniak A, Hodi FS, Flaherty KT, Lawrence DP, Lin JY. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012 Mar; 148(3):363-6.
    View in: PubMed
  32. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One. 2012; 7(1):e29622.
    View in: PubMed
  33. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011; 9(1):214.
    View in: PubMed
  34. Luke JJ, Hodi FS. Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma. Clin Cancer Res. 2012 Jan 1; 18(1):9-14.
    View in: PubMed
  35. Zhou J, Yuen NK, Zhan Q, Velazquez EF, Murphy GF, Giobbie-Hurder A, Hodi FS. Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. Cancer Immunol Immunother. 2012 May; 61(5):655-65.
    View in: PubMed
  36. O'Regan KN, Jagannathan JP, Ramaiya N, Hodi FS. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy. AJR Am J Roentgenol. 2011 Aug; 197(2):W241-6.
    View in: PubMed
  37. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27; 3(80):80ra34.
    View in: PubMed
  38. Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011 Jul 15; 17(14):4622-8.
    View in: PubMed
  39. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60.
    View in: PubMed
  40. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010 Sep 22; 102(18):1388-97.
    View in: PubMed
  41. Friedlander P, Hodi FS. Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol. 2010 Sep; 8(9):619-27.
    View in: PubMed
  42. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.
    View in: PubMed
  43. Flaherty KT, Hodi FS, Bastian BC. Mutation-driven drug development in melanoma. Curr Opin Oncol. 2010 May; 22(3):178-83.
    View in: PubMed
  44. Hodi FS, Dranoff G. The biologic importance of tumor-infiltrating lymphocytes. J Cutan Pathol. 2010 Apr; 37 Suppl 1:48-53.
    View in: PubMed
  45. Hodi FS. Overcoming immunological tolerance to melanoma: Targeting CTLA-4. Asia Pac J Clin Oncol. 2010 Mar; 6 Suppl 1:S16-23.
    View in: PubMed
  46. Schatton T, Schütte U, Frank NY, Zhan Q, Hoerning A, Robles SC, Zhou J, Hodi FS, Spagnoli GC, Murphy GF, Frank MH. Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res. 2010 Jan 15; 70(2):697-708.
    View in: PubMed
  47. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT, Landi TM, Sosman J. Melanoma from bench to bedside: meeting report from the 6th international melanoma congress. Pigment Cell Melanoma Res. 2010 Feb; 23(1):14-26.
    View in: PubMed
  48. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1; 15(23):7412-20.
    View in: PubMed
  49. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A, Martin L, Martini MC, Pruitt SK, Ross MI, Sener SF, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, Weber J, Wong MK. Melanoma. J Natl Compr Canc Netw. 2009 Mar; 7(3):250-75.
    View in: PubMed
  50. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 1; 14(23):7726-32.
    View in: PubMed
  51. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008 Nov 1; 14(21):6821-8.
    View in: PubMed
  52. Hodi FS, Fisher DE. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol. 2008 Dec; 5(12):696-7.
    View in: PubMed
  53. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008 Aug; 32(8):1130-7.
    View in: PubMed
  54. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol. 2008 Sep; 5(9):557-61.
    View in: PubMed
  55. Sittler T, Zhou J, Park J, Yuen NK, Sarantopoulos S, Mollick J, Salgia R, Giobbie-Hurder A, Dranoff G, Hodi FS. Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. Clin Cancer Res. 2008 Jun 15; 14(12):3896-905.
    View in: PubMed
  56. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 1; 26(13):2178-85.
    View in: PubMed
  57. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
    View in: PubMed
  58. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008 Apr; 222:287-98.
    View in: PubMed
  59. Anderson KS, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, LaBaer J. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008 Apr; 7(4):1490-9.
    View in: PubMed
  60. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10.
    View in: PubMed
  61. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 1; 68(3):664-73.
    View in: PubMed
  62. Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5238-42.
    View in: PubMed
  63. Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67.
    View in: PubMed
  64. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
    View in: PubMed
  65. Thompson JF, Hodi FS, Zembowicz A. Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the arm. N Engl J Med. 2007 Jan 18; 356(3):285-92.
    View in: PubMed
  66. Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9190-5.
    View in: PubMed
  67. Hodi FS. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006 Feb 1; 12(3 Pt 1):673-8.
    View in: PubMed
  68. Hodi FS, Seiden M, Butler M, Haluska FG, Kruse A, Mac Rae S, Nelson M, Mihm M, Lowy I, Allison JP, Dranoff G. . Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in previously vaccinated melanoma and ovarian cancer patients. Keystone Symposia: Advances in the understanding and treatment of melanoma. 2006.
  69. Hodi FS, Dranoff G. Combinatorial cancer immunotherapy. Adv Immunol. 2006; 90:341-68.
    View in: PubMed
  70. Hodi FS, Dranoff G. . Combinatorial Cancer Immunotherapy. in Cancer Immunotherapy – a thematic volume of Advances in Immunology. Elsevier Academic Press. 2006; 90:341-368.
  71. Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
    View in: PubMed
  72. Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 1; 11(21):7692-9.
    View in: PubMed
  73. Hodi FS, Granter S, Antin J. Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005; 5:7.
    View in: PubMed
  74. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82.
    View in: PubMed
  75. FS Hodi, M Seiden, M Butler, FG Haluska, I Lowy, E Vincent-Brunick, D Lautz, M Mihm, and G Dranoff. . Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Proceedings of ASCO. 2004.
  76. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003 Sep 1; 21(17):3343-50.
    View in: PubMed
  77. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7.
    View in: PubMed
  78. Mollick JA, Hodi FS, Soiffer RJ, Nadler LM, Dranoff G. MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3.
    View in: PubMed
  79. Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403.
    View in: PubMed
  80. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.
    View in: PubMed
  81. Schmollinger JC, Vonderheide RH, Hoar, KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, North PE, Mihm M, Kutok JL, Dranoff G. . The inhibitor of apoptosis protein ML-IAP is a target for immune mediated tumor destruction. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:3398-3403.
  82. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. . Vaccination with Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony Stimulating Factor by Adenoviral Mediated Gene Transfer Augments Anti-tumor Immunity in Patients with Metastatic Melanoma. Journal of Clinical Oncology. 2003; 21:3343-3350.
  83. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathiesen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. . Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. Journal of Clinical Oncology. 2003; 21:624-630.
  84. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002 Sep 15; 100(6):2123-31.
    View in: PubMed
  85. Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):283-6.
    View in: PubMed
  86. Tsao H, Millman P, Linette GP, Hodi FS, Sober AJ, Goldberg MA, Haluska FG. Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol. 2002 Jun; 138(6):799-802.
    View in: PubMed
  87. Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberg D, Mihm M, Dranoff G. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
    View in: PubMed
  88. Hodi FS, Wick MW. . Skin cancer. in Atlas of Diagnostic Oncology. 2002; 364-394.
  89. Hodi FS, Soiffer RJ. . Interleukins and Cancer. in Encyclopedia of Cancer. 2002; 523-535.
  90. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls, AJ, Chessia M, Barrett P, Gribben JG. . Identification of novel antigens in chronic lymphocytic leukemia by SEREX: Assessment of their potential as targets for immunotherapeutic approaches. Blood. 2002; 100:2123-2131.
  91. Haluska FG, Goldberg MA, Linette G, Jonasch E, Hodi FS, Cunningham CC, Nemunaitis J, Webb I, Stowell C, Yang S. . A phase I/II trial utilizing autologous dendritic cells transduced with gp100 and Melan A/MART-1-encoding adenoviruses in advanced melanoma. Proceedings of ASH. 2001.
  92. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45.
    View in: PubMed
  93. Haluska F, Linette G, Jonasch E, Hodi FS, Longerich S, Yang S, Webb I, Stowell C, Kaplan J, Roberts B, Goldberg M. . Immunologic Gene Therapy of Melanoma: Phase I Study of Therapy with Autologous Dendritic Cells Transduced with Recombinant Adenoviruses Encoding Melanoma Antigens. Proceedings of ASCO. 2000.
  94. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao HT, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. . Adjuvant high-dose interferon Alpha-2b in patients with high-risk melanoma. Cancer J Sci Am. 2000; 6:139-45..
  95. Hodi FS, Soiffer R, Clark J, Finkelstein D, Haluska F. . Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma. Proceedings of ASCO. 1999.
  96. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6.
    View in: PubMed
  97. Hodi FS, Dranoff G. Genetically modified tumor cell vaccines. Surg Oncol Clin N Am. 1998 Jul; 7(3):471-85.
    View in: PubMed
  98. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb; 16(2):670-82.
    View in: PubMed
  99. Hodi FS, Dranoff G. . Genetically-modified tumor vaccines. Surgical Oncology Clinics of North America. 1998; 7:471-485.
  100. Haluska FG, Hodi FS. . The molecular genetics of familial malignant melanoma. Journal of Clinical Oncology. 1998; 16:670-682.
  101. Haller DG, Catalano P, Macdonald JS, Mayer RJ, Hodi FS. . Gender as a factory influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Köln, Germany. 1995.
  102. Hodi FS, Catalano P, Macdonald JS, Mayer RJ, Haller DG. . Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Genoa, Italy. Second International Conference on Geriatric Oncology. 1994.
  103. Stadtmauer EA, Hodi FS, Sickles C, Biggs DD, Mangan P, Buzby G, Zaleta E, Silberstein L. High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer. Prog Clin Biol Res. 1994; 389:487-95.
    View in: PubMed
  104. Reidenberg MM, Hodi FS. A plea for prices in physician prescribing. JAMA. 1991 Dec 18; 266(23):3285.
    View in: PubMed
  105. Watkins DI, Chen ZW, Hughes AL, Hodi FS, Letvin NL. Genetically distinct cell populations in naturally occurring bone marrow-chimeric primates express similar MHC class I gene products. J Immunol. 1990 May 15; 144(10):3726-35.
    View in: PubMed
  106. Watkins DI, Shadduck JA, Hodi FS, Stone ME, Letvin NL. Use of cDNA probes specific for the human MHC class II beta loci for tissue-typing nonhuman primates at their class II beta loci. Transplantation. 1989 Jul; 48(1):170-3.
    View in: PubMed
  107. Watkins DI, Hodi FS, Letvin NL. A primate species with limited major histocompatibility complex class I polymorphism. Proc Natl Acad Sci U S A. 1988 Oct; 85(20):7714-8.
    View in: PubMed
  108. Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi FS, Ringler DJ, Hunt RD, King NW, et al. Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. Int J Cancer. 1988 Apr 15; 41(4):601-8.
    View in: PubMed
  109. Daniel MD, Letvin NL, Sehgal PK, Schmidt DK, Silva DP, Solomon KR, Hodi FS Jr, Ringler DJ, Hunt RD, King NW, Desrosiers RC. Prevalance of antibodies to three retroviruses in a captive colony of Macaque monkeys. International Journal of Cancer. 1988; 41:601-8.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Hodi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_